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Abstract
Background: We have previously shown evidence that polymorphisms within genes controlling leukotriene B4
(LTB4) production (ALOX5AP and LTA4H) are associated with asthma susceptibility in children. Evidence also
suggests a potential role of LTB4 in COPD disease mechanisms including recruitment of neutrophils to the lung.
The aim of the current study was to see if these SNPs and those spanning the receptor genes for LTB4 (LTB4R1 and
LTB4R2) influence baseline lung function and COPD susceptibility/severity in smokers.
Methods: Eight ALOX5AP, six LTA4H and six LTB4R single nucleotide polymorphisms (SNPs) were genotyped in a
UK Smoking Cohort (n = 992). Association with baseline lung function (FEV1 and FEV1/FVC ratio) was determined
by linear regression. Logistic regression was used to compare smoking controls (n = 176) with spirometry-defined
COPD cases (n = 599) and to more severe COPD cases (GOLD stage 3 and 4, n = 389).
Results: No association with ALOX5AP, LTA4H or LTB4R survived correction for multiple testing. However, we
showed modest association with LTA4H rs1978331C (intron 11) with increased FEV1 (p = 0.029) and with increased
FEV1/FVC ratio (p = 0.020).
Conclusions: These data suggest that polymorphisms spanning ALOX5AP, LTA4H and the LTB4R locus are not
major determinants of baseline lung function in smokers, but provide tentative evidence for LTA4H rs1978331C
(intron 11) in determining baseline FEV1 and FEV1/FVC ratio in Caucasian Smokers in addition to our previously
identified role in asthma susceptibility.
Background
Chronic obstructive pulmonary disease (COPD) is a com-
plex respiratory disease with genetic and environmental
contributors to pathophysiology [1,2]. Evidence suggests
the dihydroxy leukotriene, leukotriene B4 (LTB4), plays a
role in this disease as its production is elevated in the air-
ways of COPD subjects [3,4]. The altered inflammatory
response of the airways of COPD sufferers is a result of
lymphocytes and neutrophils, suggested in part to be the
result of cigarette smoke inhalation [5]. Importantly, LTB4
has been shown to have chemotactic activity recruiting
inflammatory cells to the lung [6,7]. LTB4 is implicated in
the neutrophillic inflammation of COPD and has been
suggested as the major chemotactic agent in more severe
forms of this disease [8]. It has been established that the
cysteinyl leukotrienes (CysLTs; LTC4,L T D 4 and LTE4)
play a significant role in bronchoconstriction and airway
inflammation in asthma [9] but their role in COPD is less
clear.
Studies have suggested that polymorphisms spanning
leukotriene pathway genes may be important in deter-
mining leukotriene production and susceptibility to aller-
gic disorders, such as asthma [10]. LTB4 and the CysLTs
are produced from arachidonic acid in a multi-enzyme
pathway called the 5-lipoxygenase (5-LO) pathway. Single
nucleotide polymorphisms (SNPs) in two 5-LO pathway
genes; 5-lipoxygenase activating protein (ALOX5AP)a n d
leukotriene A4 hydrolase (LTA4H) have shown an asso-
ciation with LTB4 overproduction from ionomycin-
stimulated neutrophils and with myocardial infarction
(MI) susceptibility [11,12]. 5-lipoxygenase activating
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any medium, provided the original work is properly cited.protein (FLAP) with 5-LO is involved in the synthesis of
LTA4 which can be conjugated with glutathione by LTC4
synthase to form LTC4 and subsequent CysLTs or con-
verted to LTB4 b yt h ee n z y m eL T A 4 hydrolase (LTA4H)
[13]. FLAP is involved in the production of all leuko-
trienes; however LTA4H is specifically involved in LTB4
production.
A recent study has suggested that LTA4Hc o n t a i n sa n
aminopeptidase activity as well as having a role in LTB4
production [14]. This aminopeptidase activity cleaves the
neutrophil chemoattractant proline-glycine-proline (PGP),
a COPD biomarker, responsible for the influx of neutro-
phils into the lung - contributing to chronic inflammation.
Cigarette smoke was found to inhibit this aminopeptidase
activity thereby leading to accumulation of PGP and neu-
trophils [14]. This dual role could have important conse-
quences for the design of therapeutics targeting LTA4H.
We have recently reported evidence that SNPs spanning
ALOX5AP and LTA4H are asthma susceptibility markers
[15]. SG13S114A, SG13S89A and SG13S41G (ALOX5AP)
and rs1978331C (LTA4H) were associated with asthma
and asthma related phenotypes (atopy, FEV1,b r o n c h i a l
hyperresponsiveness) in a family based association study
using 341 asthma families with two affected siblings [15].
Several haplotype associations were also observed [15]. To
date, no study has investigated the role of these SNPs with
respect to COPD or baseline lung function in smokers.
Smoking is associated with decline in lung function and is
a major risk factor for the development of COPD; we
therefore investigated the role of ALOX5AP, LTA4H and
LTB4R SNPs in smokers.
The aim of the current study was to determine whether
polymorphisms spanning ALOX5AP, LTA4H and the
LTB4R locus influence baseline lung function (FEV1 and
FEV1/FVC ratio) in smokers and whether they contribute
to susceptibility to develop COPD or a more severe form
of COPD in smokers. We genotyped twenty SNPs span-
ning these three loci in a cohort recruited for COPD or
smoking history (n = 992 subjects) and completed a series
of association analyses.
Methods
Subjects and baseline characteristics
Subjects were recruited from five UK centres for smok-
ing history and/or COPD diagnosis (n = 992) [16]. Sub-
jects collected from Nottingham (n = 537) were
Caucasian, > 40 years and had > 10 pack-year smoking
history. Subjects collected from other UK centres (n =
455) were recruited for physician and spirometry
defined COPD, Caucasian, > 40 years, smokers with >
10 pack-year history. The combined subjects (n = 992)
recruited for smoking history or COPD diagnosis was
stratified into ‘healthy’ smokers (smoking controls) (n =
176, post-bronchodilator (BD) salbutamol FEV1 >8 0 %
predicted and postBD FEV1/FVC > 0.7) and COPD
cases (n = 599, postBD FEV1 <8 0 %p r e d i c t e da n d
postBD FEV1/FVC ratio < 0.7). Subjects not meeting
these criteria (or with missing data) were excluded from
the case control analyses (n = 217). To investigate
whether SNPs determined severity of COPD in the smo-
kers we compared smoking controls with postBD spiro-
metry, i.e. the GOLD classifications [17]. Ethical
approval was obtained from the relevant ethics commit-
tees (Nottingham, Sheffield, Manchester, Leicester and
Oxford) and informed consent from all subjects was
obtained.
Selection of SNPs and genotyping
Twenty SNPs were genotyped across ALOX5AP (eight),
LTA4H (six) and LTB4R (six) (Figure 1A-C). SNPs span-
ning ALOX5AP and LTA4H have previously been shown
to tag haplotypes associated with myocardial infarction
and LTB4 production [11,12] and with asthma suscept-
ibility in our recent study [15]. Six LTB4R SNPs were
chosen for their ability to tag linkage disequilibrium
(LD) blocks or for inferred function, once the region
had been sequenced in Caucasian individuals (22 SNPs
validated in 35 Caucasian subjects, data not shown).
Genotyping was completed by Kbioscience (Hertford-
shire, UK) using KASPar technology. Hardy-Weinberg
equilibrium was assessed in all subjects using Haploview
software [18].
Statistical analyses
Linear regression (SPSS V15, SPSS Inc., Chicago, IL)
was used to determine the contribution of each SNP to
baseline FEV1 (litres) or FEV1/FVC ratio using the addi-
tive model (e.g. AA vs. AC vs. CC) including age, gen-
der, height and smoking pack-years as covariates. The
COPD susceptibility analyses were completed using
logistic regression in the additive model in two ways.
Firstly, the smoking controls (n = 176) vs. all COPD
subjects (n = 599) and then the smoking controls (n =
176) vs. GOLD 3 and 4 subjects (n = 389). Both analyses
included age, gender and pack-years as covariates (Table
1). Based on the 80 tests completed (analysis of 20 SNPs
with 4 outcomes), a conservative Bonferroni correction
s u g g e s t e dap<1 0
-4 when reporting results as signifi-
cant. With respect to power (based on lowest and high-
est minor allele frequency),t h e r ew a sb e t w e e n7 7 - 9 9 %
power to detect a 50 ml difference in FEV1 and between
58-99% power to detect a 5% difference in FEV1/FVC
ratio. Analyses of COPD susceptibility were relatively
underpowered, with between 28-91% power with an
odds ratio of 1.5 and 68-99% power with an odds ratio
of 2.0. All analyses considered an error rate of 5%.
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Clinical characteristics and genotyping
Subject characteristics for the smoking controls (n = 176)
and COPD subjects (n = 599) and the entire cohort (n =
992) are shown (Table 1). Comparison of the smoking
controls (n = 176) and COPD sufferers (n = 599) show
differences in baseline lung function (percent predicted
FEV1 96.03% compared to 40.31%) as anticipated (p <
0.0001). These subjects also showed differences for age,
gender and pack-years so these variables were included
as covariates in analyses. Genotyping completion rates
were > 96% for all twenty SNPs genotyped and did not
show deviation from Hardy-Weinberg equilibrium (p >
0.05). Minor allele frequencies for ALOX5AP and LTA4H
SNPs were similar to those observed in our previous
study [15].
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Figure 1 Location of SNPs genotyped in ALOX5AP, LTA4H and LTB4R in the smokers and linkage disequilibrium (LD) plot. The LD plot
shows the LD displayed as D’/LOD in Haploview software. Numerical values shown correspond to D’. A-C. represents the physical location of the
SNPs genotyped in ALOX5AP, LTA4H and LTB4R, respectively. Black boxes represent exons and the spaces between represent introns. D. E. and F.
represents the LD plot in the smokers (n = 992) for each loci respectively..* represents SNPs that define the haplotype HapA, #which define
HapB and ^ which define the haplotype (HapK) previously associated with MI [11,12].
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Page 3 of 10Table 1 Baseline characteristics of the study populations
UK Smoking
Cohort
Smoking
Controls
COPD
Cases
GOLD stage 3 and
4
Comparison (smoking controls vs. COPD
cases
Comparison (smoking controls vs. GOLD
3/4
Age 63.33 ± 10.29 54.38 ± 9.52 65.96 ± 9.01 67.16 ± 8.56 p < 0.0001 p < 0.0001
Female (%) 43.8 56.3 39.9 38.8 p = 0.037 p = ns
Baseline FEV1 %
predicted
56.05 ± 28.16 96.03 ±
12.15
40.31 ±
15.63
31.46 ± 8.69 p < 0.0001 p < 0.0001
FEV1/FVC Ratio 55.34 ± 17.43 77.30 ± 5.90 46.3 ± 12.5 41.57 ± 11.20 p < 0.0001 p < 0.0001
Post BD FEV1 %
predicted
59.08 ± 27.14 99.48 ±
11.72
44.65 ±
15.52
35.28 ± 8.90 p = 0.049 p < 0.0001
PostBD FEV1/FVC Ratio 55.58 ± 17.71 79.10 ± 5.05 46.2 ± 12.00 41.27 ± 10.46 p < 0.0001 p < 0.0001
Pack Years 43.54 ± 26.05 32.74 ±
20.04
47.61 ±
27.01
47.96 ± 27.85 p < 0.0001 p < 0.0001
GOLD Stage (%):
￿ Stage 1 6.9 0.0 0.0 0.0
￿ Stage 2 32.6 0.0 34.8 0.0
￿ Stage 3 42.4 0.0 45.5 69.9
￿ Stage 4 18.2 0.0 19.7 30.1
Number 992 176 599 389
FEV1, Forced expiratory volume in one second; FVC, forced vital capacity; BD, bronchodilator. Control subjects were defined as having postBD (salbutamol) FEV1 > 80% and postBD FEV1/FVC > 0.7. Subjects with
COPD were defined as having postBD FEV1 < 80% and FEV1/FVC < 0.7. Individuals who did not meet these criteria were excluded from analyses. Continual variables between groups were compared by Independent
T-Test, categorical variables by Pearson chi square.
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Figure 1 panels A-C show the location of the SNPs geno-
typed across ALOX5AP, LTA4H and the LTB4R locus
respectively. Panel D shows the linkage disequilibrium
(LD) pattern of SNPs genotyped across the ALOX5AP
gene on chromosome 13q12. Within ALOX5AP regions of
high LD (measured by D’) include between SG13S25
(5’UTR) and SG13S114 (intron 1) and of low LD include
between SG13S114 (intron 1) and rs38032777 (intron 2).
SNPs defining the region SG13S25 (5’UTR) and SG13S35
(3’UTR) show relatively high LD with all other SNPs.
Panel E shows the genotyped SNPs for the LTA4H gene
on chromosome 12q22. For LTA4H there are regions of
high LD between rs17677715 (intron 6) and rs2660899
(5’UTR) and rs2540482 (5’UTR) and rs2660845 (5’UTR).
The two distal SNPs defining the extended region are not
in strong LD with others. Panel C shows the SNPs geno-
typed across the LTB4R1 and LTB4R2 genes. There was
high LD between all SNPs genotyped in the LTB4R locus
indicating there was some redundancy in genotyping
(Panel F).
Polymorphisms spanning ALOX5AP, LTA4H and LTB4R are
not associated with baseline FEV1 and FEV1/FVC in
smokers
To assess whether SNPs in ALOX5AP, LTA4H and LTB4R
influence baseline lung function in smokers we deter-
mined their role in baseline FEV1 and FEV1/FVC in the
entire population (n = 992) using linear regression in the
additive model (Additional File 1 Table S1). The FEV1
analyses did not identify any significant association with
ALOX5AP, LTA4H or LTB4R SNPs. LTA4H rs1978331C
(intron 11) (p = 0.029, mean FEV1 values: TT 1.468 ±
0.039L, TC 1.599 ± 0.034L and CC 1.594 ± 0.057L) and
rs2660899 (5’UTR) (p = 0.024; GG 1.580 ± 0.030L, GT
1.504 ± 0.044L and TT 1.192 ± 0.158L) were associated
with increased FEV1, although this did not meet Bonfer-
roni correction. Analysis with FEV1/FVC ratio again did
not show any significant association. However, the same
LTA4H rs1978331C (intron 11) showed p = 0.020 with the
same direction of effect, increased FEV1/FVC ratio (mean
ratio ranging from 53.8% in the major homozygotes to
57.4% in the minor homozygotes).
Polymorphisms spanning ALOX5AP, LTA4H and LTB4R do
not determine COPD susceptibility
To determine whether SNPs spanning ALOX5AP,
LTA4H and LTB4R act as determinants of COPD sus-
ceptibility in smokers, we completed case-control asso-
ciation analyses comparing the smoking controls (n =
176) with the COPD subjects (n = 599), defined by post-
bronchodilator spirometry (Table 2). No significant asso-
ciations were observed. This analysis was corrected for
age, gender and pack-years as these traits were signifi-
cantly different between the study groups (Table 1).
Polymorphisms spanning ALOX5AP, LTA4H and LTB4R do
not determine susceptibility to develop severe COPD
Subjects (where data available) were stratified according
to GOLD classifications using post-bronchodilator lung
function (GOLD 1 = 44 individuals, GOLD 2 = 209,
GOLD 3 = 273 and GOLD 4 = 117). The phenotypic
characteristics of these GOLD stratified COPD patients
have been previously reported [16]. We did not observe
any significant associations with any of the SNPs tested
in the control (n = 176) versus severe COPD (n = 389)
analyses. rs3803277 (ALOX5AP,i n t r o n2 )s h o w e dp r o -
tective association (OR = 0.72, 95% CI = 0.52-0.99, p =
0.045), but this did not survive correction (Table 3).
Discussion
This was the first study to investigate polymorphisms
spanning genes involved with LTB4 production and
activity with lung function and COPD susceptibility in
smokers. A UK smoking cohort comprising n = 992
individuals with > 40 years and > 10 pack-years smoking
history was used to determine whether SNPs in
ALOX5AP, LTA4H and LTB4R influenced baseline lung
function and susceptibility to develop COPD in smokers.
LTB4 has been shown to be important for the inflamma-
tion observed in COPD, with this mediator upregulated
in COPD subjects [4]. We hypothesised that polymorph-
isms in these genes may influence susceptibility to
develop airway obstruction in smokers that is in part
driven by LTB4.W eh a v ef o u n dt h a tp o l y m o r p h i s m s
spanning ALOX5AP, LTA4H and the LTB4R locus are
not associated with lung function or COPD susceptibil-
ity in smokers as no SNP survived correction for multi-
ple testing. However, we provide tentative evidence for
association between LTA4H rs1978331C (intron 11) and
lung function measures in these subjects.
We have previously investigated the role of polymorphic
variation in the genes of the 5-lipoxygenase pathway e.g.
ALOX5, LTC4S, CYSLTR1 in asthma and allergy suscept-
ibility [15,19,20] and as determinants of clinical responses
to therapies targeting this pathway [21]. These studies pro-
vide accumulating evidence that polymorphic variation in
these genes influence disease phenotypes in disorders
where leukotrienes play a significant role [10], also con-
firmed with other non-respiratory diseases e.g. MI [11,12].
To date, no study has specifically looked at genetic deter-
minants of leukotriene production/activity in smokers
with or without COPD. While no association survived the
Bonferroni correction, additive model analyses with
rs1978331C (LTA4H, intron 11) showed a p = 0.029 with
an increase in FEV1 and p = 0.020 with FEV1/FVC ratio.
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Page 5 of 10The mean FEV1 and FEV1/FVC values for the TC hetero-
zygotes and CC homozygotes were similar, but the pre-
sence of the minor C-allele for these genotype groups gave
higher trait values when compared to the TT homozy-
gotes, suggesting a dosage effect does not occur. These
findings provide tentative evidence suggesting that variants
in LTA4H may determine lung function in COPD.
We next sought to investigate whether polymorphisms
spanning these genes determine susceptibility to develop
COPD. Case-control association analyses were completed
with ‘healthy’ control smokers and smokers with physician
diagnosed COPD (including spirometry). No significant
associations with polymorphisms spanning ALOX5AP,
LTA4H and LTB4R were identified. We also completed
another case-control analysis involving COPD sufferers at
the severe end of the spectrum. GOLD groups 3 and 4
were chosen as this represented the most severe cases
based on spirometry. Again no significant associations
were observed.
There is an interesting link for LTA4H with COPD and
asthma; in our group’sp r e v i o u ss t u d y ,w es h o w e dp r e l i -
minary association with rs1978331C (LTA4H,i n t r o n1 1 )
and asthma susceptibility in 341 families (protection, p =
0.036) [15]. A recent study has shown a similar effect in a
different disease; heterozygosity at two LTA4H SNPs, one
rs1978331 (intron 11), is significantly associated with
protection from tuberculosis infection, lower mortality
amongst patients with severe tuberculosis infection and
protection from the development of severe leprosy dis-
ease [22]. These two studies show the same protective
direction of association and provide further support for a
functionally significant role of rs1978331 or (another
SNP tagged by this) in determining LTA4H expression or
activity.
Suggestive association with COPD (p = 0.02 to 0.05)
with four LTA4H SNPs within the promoter region (these
S N P sw e r en o ta n a l y s e di no u rc u r r e n ts t u d y )w a s
reported by another group [23]. We have not identified
any association with LTA4H SNPs located in the 5’UTR
(rs2540482, rs2660845 and rs2540475) with lung function
or COPD susceptibility in smokers. Interestingly, this
group also tested different ALOX5AP SNPs to our current
study and found no association with COPD [23]. These
and our own data provide suggestive support for a role of
Table 2 ALOX5AP, LTA4H and LTB4R SNPs and COPD susceptibility in smokers
SNP Location Controls (n = 176) COPD (n = 599) Additive
0 1 2 MAF 0 1 2 MAF p-value Odds ratio 95%CI
ALOX5AP
SG13S25 (G/A) 5’UTR 138 35 2 0.11 491 100 5 0.09 0.556 0.87 0.55-1.37
SG13S114 (T/A) Intron 1 92 63 20 0.29 248 282 58 0.34 0.198 1.22 0.90-1.65
rs3803277 (C/A) Intron 2 54 80 42 0.47 184 303 103 0.43 0.318 0.87 0.65-1.15
SG13S89 (G/A) Intron 3 162 13 0 0.04 551 45 1 0.04 0.771 0.90 0.43-1.88
rs4468448 (C/T) Intron 4 100 65 11 0.25 333 226 34 0.25 0.807 1.04 0.76-1.45
SG13S32 (C/A) Intron 4 42 88 43 0.49 162 302 130 0.47 0.351 0.87 0.66-1.16
SG13S41 (A/G) Intron 4 149 21 0 0.06 524 62 6 0.06 0.542 0.84 0.47-1.48
SG13S35 (G/A) 3’UTR 146 26 0 0.06 479 97 3 0.09 0.970 1.01 0.60-1.71
LTA4H
rs1978331 (T/C) Intron 11 66 81 27 0.39 223 257 109 0.40 0.419 0.89 0.68-1.18
rs17677715 (T/C) Intron 6 115 50 6 0.18 372 188 26 0.20 0.899 1.02 0.72-1.46
rs2660899 (G/T) 5’UTR 130 45 1 0.13 418 158 16 0.16 0.113 1.39 0.93-2.08
rs2540482 (T/C) 5’UTR 107 58 8 0.21 358 195 34 0.23 0.473 1.13 0.81-1.58
rs2660845 (A/G) 5’UTR 92 71 12 0.26 328 224 40 0.26 0.483 0.89 0.65-1.22
rs2540475 (C/T) 5’UTR 108 55 5 0.19 358 186 27 0.21 0.770 0.95 0.67-1.35
LTB4R2
rs2332320 (T/C) 5’UTR 130 34 5 0.13 440 124 13 0.13 0.977 1.01 0.67-1.52
rs11158635 (G/T) 5’UTR 100 57 9 0.23 367 193 26 0.21 0.165 0.78 0.55-1.11
rs2516564 (C/T) 5’UTR 104 59 9 0.22 372 193 25 0.21 0.169 0.79 0.56-1.11
LTB4R1
rs2224122 (C/G) 5’UTR 102 55 9 0.22 363 190 28 0.21 0.232 0.81 0.57-1.15
rs1046587 (G/A) 3’UTR 43 94 36 0.48 155 298 128 0.48 0.566 1.09 0.82-1.45
rs3181384 (C/T) 3’UTR 100 58 10 0.20 363 191 28 0.21 0.111 0.76 0.54-1.07
Logistic regression was used to compare genotype frequencies between smoking controls (n = 176) and total COPD cases (n = 599) using the additive model
with the covariates age, gender and pack-years. OR, odds ratio; 95% CI, 95% confidence interval. 0, 1 and 2 represent the number of major homozygote,
heterozygote and minor homozygote genotype frequencies.
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smokers potentially suggesting a role for genetically deter-
mined LTB4 in COPD (LTA4H converts LTA4 to LTB4).
This may be a result of neutrophilic inflammation being
important in COPD and severe COPD [24]. While this
study did not show significant protective association with
LTA4H rs1978331C with lung function in smokers, the
same direction of effect was observed with asthma sus-
ceptibility in our previous study [15] and with the HapK
(rs1978331(T/C), rs17677715(T/C), rs2540482(T/C),
rs2660845(A/G) and rs2540475(C/T)) haplotype associa-
tion that conferred a modest risk of myocardial infarction
in Icelandic subjects for rs1978331T [12]. As previously
mentioned, a protective effect has also been observed with
tuberculosis infection [22].
LTA4H has a pro-inflammatory role generating LTB4
through its epoxide-hydrolase activity (intracellular) and
an anti-inflammatory role through its amino-peptidase
activity to breakdown PGP, facilitating resolution (extra-
cellular). Cigarette smoke selectively inhibits the ability of
LTA4H to break-down PGP leading to neutrophil accu-
mulation and contributing to COPD pathogenesis [14].
rs1978331 may affect the levels of transcription of the
LTA4H gene. Decreased transcription could lead to
decreased protein levels of LTA4H which may contribute
to the protective physiological effect, through reduction
in the formation of the inflammatory LTB4. However,
this mechanism would lead to the accumulation of PGP
and so neutrophillic inflammation, counteracting the
situation. LTB4 and PGP are both neutrophil chemoat-
tractants [25,26]. rs1978331 may alter splicing efficiency
of LTA4H. rs1978331 is in intron 11 of the gene and
exon 10 and 11 of LTA4H contains the zinc-binding
domain which is required for both the epoxide hydrolase
and aminopeptidase activities [27]. The two functional
sites are different but overlapping [28]. Altered splicing
in this region could affect the ability of LTA4H to gener-
ate LTB4 and/or degrade PGP. Presence of the C-allele
may cause splicing events that reduce LTB4 formation,
but the aminopeptidase activity may remain functional,
which could lead to less neutrophil chemotaxis and so
less inflammation. Presence of the T-allele may cause
splicing events that lead to increased LTB4 production.
The T-allele in HapK was functionally associated with
Table 3 ALOX5AP, LTA4H and LTB4R SNPs and severe COPD (defined by GOLD stage 3 and 4) in smokers
SNP Location Controls (n = 176) GOLD 3 and 4 (n = 389) Additive
0 1 2 MAF 0 1 2 MAF p-value Odds ratio 95%CI
ALOX5AP
SG13S25 (G/A) 5’UTR 138 35 2 0.11 325 60 2 0.09 0.231 0.72 0.42-1.23
SG13S114 (T/A) Intron 1 92 63 20 0.29 164 180 36 0.33 0.282 1.21 0.86-1.70
rs3803277 (C/A) Intron 2 54 80 42 0.47 122 203 58 0.42 0.045 0.72 0.52-0.99
SG13S89 (G/A) Intron 3 162 13 0 0.04 356 32 0 0.04 0.701 0.85 0.36-1.99
rs4468448 (C/T) Intron 4 100 65 11 0.25 221 146 18 0.24 0.882 0.97 0.67-1.41
SG13S32 (C/A) Intron 4 42 88 43 0.49 110 199 78 0.46 0.195 0.81 0.58-1.12
SG13S41 (A/G) Intron 4 149 21 0 0.06 343 38 4 0.06 0.293 0.71 0.37-1.35
SG13S35 (G/A) 3’UTR 146 26 0 0.06 312 61 2 0.09 0.677 0.88 0.49-1.59
LTA4H
rs1978331 (T/C) Intron 11 66 81 27 0.39 153 165 62 0.38 0.090 0.76 0.56-1.04
rs17677715 (T/C) Intron 6 115 50 6 0.18 241 124 15 0.21 0.808 1.05 0.71-1.56
rs2660899 (G/T) 5’UTR 130 45 1 0.13 264 109 10 0.17 0.114 1.44 0.92-2.26
rs2540482 (T/C) 5’UTR 107 58 8 0.21 231 129 19 0.22 0.677 1.08 0.74-1.58
rs2660845 (A/G) 5’UTR 92 71 12 0.26 209 154 22 0.26 0.452 0.87 0.61-1.25
rs2540475 (C/T) 5’UTR 108 55 5 0.19 236 118 16 0.20 0.895 0.97 0.65-1.45
LTB4R2
rs2332320 (T/C) 5’UTR 130 34 5 0.13 287 81 8 0.13 0.523 1.17 0.73-1.86
rs11158635 (G/T) 5’UTR 100 57 9 0.23 235 131 16 0.21 0.195 0.77 0.52-1.15
rs2516564 (C/T) 5’UTR 104 59 9 0.22 238 130 15 0.21 0.195 0.77 0.52-1.14
LTB4R1
rs2224122 (C/G) 5’UTR 102 55 9 0.22 228 130 18 0.22 0.365 0.83 0.56-1.23
rs1046587 (G/A) 3’UTR 43 94 36 0.48 95 195 83 0.48 0.857 1.03 0.75-1.42
rs3181384 (C/T) 3’UTR 100 58 10 0.20 230 131 18 0.22 0.183 0.77 0.52-1.13
Logistic regression was used to compare genotype frequencies between smoking controls (n = 176) and GOLD stage 3/4 cases (n = 389) using the additive
model with the covariates age, gender and pack-years. OR, odds ratio; 95% CI, 95% confidence interval. 0, 1 and 2 represent the number of major homozygote,
heterozygote and minor homozygote genotype frequencies. Black bold indicated (p = ≤ 0.05).
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phils in MI patients [12]. Other factors could complicate
this potential mechanism, such as the lung environments
in asthma and COPD and the presence/absence of cigar-
ette smoke. This information could have important con-
sequences for the design of any therapeutics inhibiting
LTA4H. Reducing LTA4H activity will reduce LTB4 pro-
duction, but neutrophilic inflammation will persist as
PGP will no longer be degraded. A more selective inhibi-
tor strategy would be required to block LTB4 production,
but leave the aminopeptidase activity intact. This could
take advantage of the different substrate specificities of
the non-overlapping regions of the ‘active site’,s m a l l
molecules which bind to this hydrophobic part of the site
can alter the substrate preference of the aminopeptidase
activity [28]. Consideration of both LTB4 and PGP and
consideration of the SNPs spanning LTA4H will be
required when designing therapeutics.
This is the first study investigating lung function in
smokers and genetic variants specific to genes involved
with LTB4 production and activity. Overall we have iden-
tified that polymorphisms spanning ALOX5AP, LTA4H
and LTB4R are not major determinants of lung function
in smokers. However, these data highlight the potential
importance of LTA4H polymorphisms in particular
rs1978331C (LTA4H, intron 11). Although the rs1978331
association did not survive correction for multiple test-
ing, the previous associations with; asthma/lung function
[ 1 5 ] ,M I[ 1 2 ]a n dT B[ 2 2 ]s u g g e s ti tm a yb eat r u ea s s o -
ciation of modest effect size and this SNPs does influence
LTA4H expression and/or activity. While no association
survived the Bonferroni correction, additive model ana-
lyses with rs1978331C (LTA4H, intron 11) showed a p =
0.029 with an increase in FEV1 and p = 0.020 with FEV1/
FVC ratio. The mean FEV1 and FEV1/FVC values for the
TC heterozygotes and CC homozygotes were similar, but
the presence of the minor C-allele for these genotype
groups gave higher trait values when compared to the
TT homozygotes, suggesting a dosage effect does not
occur. For rs1978331 TT versus TC genotype groups
there was a 131 ml difference in FEV1 and for TT versus
CC a 126 ml difference in FEV1 was observed. The level
of FEV1 at a given time depends on 1) the maximum
lung function obtained during development, and 2) the
rate of decline of lung function with age. Lung function
reaches a maximum by age 25-35 years [29]. In smokers
the rate of decline in FEV1 is accelerated and has been
calculated to be ~38.2 ml/year in males and 23.9 ml/year
in females [29] therefore the differences observed
between LTA4H rs1978331 genotypes can be considered
clinically relevant and equate to > 3 years decline in
FEV1. These findings therefore provide tentative evidence
suggesting that variants in LTA4H may determine clini-
cally relevant lung function levels in smokers.
It is important to acknowledge the limitations of our
study. Other SNPs spanning these large genes could be
important. There may also be another functional variant
in linkage disequilibrium with rs1978331. We cannot
exclude the contribution of polymorphisms spanning
other 5-LO pathway genes e.g. ALOX5, although existing
data did not support their inclusion [20,30,31]. The
magnitude of effect of SNPs are modest but in line with
the predicted relative risk attributed to a single SNP in a
single gene in complex disorders. Finally, the number of
i n d i v i d u a l su s e di nt h i ss t u d yw a sm o d e s ta n dw eh a v e
not completed extensive replication in multiple cohorts
and so caution is required in the interpretation of our
novel findings. To our knowledge these SNPs did not
show association with lung function and/or COPD in
recent GWAS studies. We have also completed a com-
prehensive look up of genes previously associated with
lung function including LTA4H and ALOX5AP in
20,288 individuals from the general population (the
SpiroMeta consortium) and did not identify these genes
as containing major determinants of lung function in
this large general population cohort [32].
Conclusions
In conclusion, these data did not confirm the hypothesis
that polymorphisms in genes specific to LTB4 produc-
tion and activity are major determinants of baseline
lung function in smokers and do not determine suscept-
ibility to develop COPD. However, rs1978331 (LTA4H,
intron 11) may have a modest effect on lung function
parameters in smokers. Heterozygosity of this poly-
morphism has previously been correlated with LTB4
production, asthma and TB. These findings may be
important when considering potential approaches to tar-
get LTA4H in COPD.
Additional material
Additional file 1: Baseline lung function (FEV1 and FEV1/FVC ratio)
and ALOX5AP, LTA4H and LTB4R SNPs in the smokers (n = 992). This
table shows the results of the association analysis between leukotriene
pathway SNPs and baseline FEV1 and FEV1/FVC using the additive model.
Covariates included in the model were age, gender, height and pack
years. Associations with p < 0.05 are shown in bold black.
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